We have located links that may give you full text access.
Inter-heterogeneity and intra-heterogeneity of α v β 3 in non-small cell lung cancer and small cell lung cancer patients as revealed by 68 Ga-RGD 2 PET imaging.
PURPOSE: Integrin αv β3 is the therapeutic target of the anti-angiogenic drug cilengitide. The objective of this study was to compare αv β3 levels in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients, by using the positron emission tomography (PET) tracer 68 Ga-labeled dimerized-RGD (68 Ga-RGD2 ).
METHODS: Thirty-one patients with pathologically confirmed lung cancer were enrolled (21 were NSCLC and 10 were SCLC). PET/CT images were acquired using 68 Ga-RGD2 .18 F-FDG PET/CT images were also acquired on the consecutive day as reference. The standard uptake values (SUV) and the tumor/nontarget (T/NT) values were quantitatively compared. Expression of the angiogenesis marker αv β3 in NSCLC and SCLC lesions was analyzed by immunohistochemistry.
RESULTS: The 18 F-FDG SUVmax and the SUVmean were not significantly different between NSCLC and SCLC patients. The 68 Ga-RGD2 uptake of SCLC patients was at background levels in both SUV and T/NT measurements and was significantly lower than that of NSCLC patients. The range value of 68 Ga-RGD2 SUVmean was 4.5 in the NSCLC group and 2.2 in the SCLC group, while the variation coefficient was 36.2% and 39.3% in NSCLC and SCLC primary lesions, respectively. Heterogeneity between primary lesions and putative distant metastases was also observed in some NSCLC cases. Immunostaining showed that αv β3 integrin was expressed in the cells and neovasculature of NSCLC lesions, while SCLC samples had negative expression.
CONCLUSIONS: The uptake of 68 Ga-RGD2 in SCLC patients is significantly lower than that in NSCLC patients, indicating a lower αv β3 target level for cilengitide in SCLC. Apparent intra-tumor heterogeneities of αv β3 also exist in both NSCLC and SCLC. Such inter- and intra-heterogeneity of αv β3 may potentially improve current applications of αv β3 -targeted therapy and diagnostic imaging in lung cancer.
METHODS: Thirty-one patients with pathologically confirmed lung cancer were enrolled (21 were NSCLC and 10 were SCLC). PET/CT images were acquired using 68 Ga-RGD2 .18 F-FDG PET/CT images were also acquired on the consecutive day as reference. The standard uptake values (SUV) and the tumor/nontarget (T/NT) values were quantitatively compared. Expression of the angiogenesis marker αv β3 in NSCLC and SCLC lesions was analyzed by immunohistochemistry.
RESULTS: The 18 F-FDG SUVmax and the SUVmean were not significantly different between NSCLC and SCLC patients. The 68 Ga-RGD2 uptake of SCLC patients was at background levels in both SUV and T/NT measurements and was significantly lower than that of NSCLC patients. The range value of 68 Ga-RGD2 SUVmean was 4.5 in the NSCLC group and 2.2 in the SCLC group, while the variation coefficient was 36.2% and 39.3% in NSCLC and SCLC primary lesions, respectively. Heterogeneity between primary lesions and putative distant metastases was also observed in some NSCLC cases. Immunostaining showed that αv β3 integrin was expressed in the cells and neovasculature of NSCLC lesions, while SCLC samples had negative expression.
CONCLUSIONS: The uptake of 68 Ga-RGD2 in SCLC patients is significantly lower than that in NSCLC patients, indicating a lower αv β3 target level for cilengitide in SCLC. Apparent intra-tumor heterogeneities of αv β3 also exist in both NSCLC and SCLC. Such inter- and intra-heterogeneity of αv β3 may potentially improve current applications of αv β3 -targeted therapy and diagnostic imaging in lung cancer.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app